Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950385 | 0.87 | LMNA (0.53) | ESR1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL8900698 | 0.85 | RAB9A (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11833488 | 0.84 | TSHR (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7492169 | 0.84 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6948241 | 0.84 | ESR1 (0.54) | ESR1LMNACYP1A2CYP3A4NPC1 | |
| SCHEMBL6426350 | 0.83 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9658861 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6950073 | 0.82 | ALDH1A1 (0.47) | NPC1RAB9AMAPTALDH1A1TSHR | |
| SCHEMBL9187932 | 0.81 | TSHR (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11839343 | 0.81 | ALOX15 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | claimed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8350995-B2 | Optical film, production method of optical film, optically-compensatory film, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2013-01-08 | — | — | US | disclosed |
| CN-101326044-B | Polarizing plate protective film, method for producing film, polarizing plate, and liquid crystal display device | KONICA MINOLTA OPTO INC | 2012-05-23 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8147638-B2 | Polarizing plate and display using the same | KONICA MINOLTA OPTO INC. (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110155306-A1 | POLARIZING PLATE AND DISPLAY USING THE SAME | KONICA MINOLTA OPTO, INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7968019-B2 | Optical compensation film, method for producing optical compensation film, polarization plate and liquid crystal display | KONICA MINOLTA OPTO, INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7939002-B2 | Retardation film, method for producing the same, polarizing plate and liquid crystal display | KONICA MINOLTA OPTO, INC. (JP) | 2011-05-10 | — | — | US | disclosed |
| CN-1067992-C | Substituted thiazolidine derivatives and pharmaceutical compositions containing them and use thereof | OTSUKA PHARMA CO LTD (JP) | 2001-07-04 | — | — | CN | disclosed |
| EP-0936218-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| CN-1184105-A | Substituted thiazolidine derivatives and pharmaceutical compositions containing them and use thereof | OTSUKA PHARMA CO LTD (JP) | 1998-06-10 | — | — | CN | disclosed |
| CN-1037842-C | Substituted thiazolidine derivatives, pharmaceutical compositions and uses thereof | OTSUKA PHARMA CO LTD (JP) | 1998-03-25 | — | — | CN | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| CN-1106982-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | CA12 4586/4885CA1 3746/4885CA2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.